期刊文献+

依非韦伦中间体的不对称合成

Asymmetric Synthesis of Efavirenz Intermediates
下载PDF
导出
摘要 为了优化依非韦伦手性中间体(S)-1-(2-氨基-5-氯苯基)-1-三氟甲基-3-环丙基-2-丙炔-1-醇的不对称合成工艺。以对氯苯胺为起始原料,经过氨基保护、酰化反应、氨基脱保护、碱化、不对称加成得到目标化合物。所得化合物结构均经核磁共振氢谱和碳谱确证。得到不对称加成反应最佳工艺条件:2-甲基四氢呋喃/甲苯为溶剂,4-氯-2-(三氟乙酰基)苯胺的浓度为0.45 mol/L,4-氯-2-(三氟乙酰基)苯胺、(1R,2S)-1-苯基-2-(吡咯烷基)-1-丙醇与ZnCl2的摩尔比为1.0∶1.2∶1.3,总收率达79.8%(以对氯苯胺计),对映体过量98.2%。优化后的工艺条件具有成本低、收率高,适合工业生产的特点。 To improve the asymmetric synthesis process of chiral intermediate(S)-1-(2-amino-5-chlorophenyl)-1-trifluoromethyl-3-cyclopropyl-2-propyne-1-ol of efavirenz,we prepared the target compound via amino protection,acylation reaction,deprotection,alkalinization and asymmetric addition reaction with p-chloroaniline as the raw material.The chemical structure of compounds was confirmed by 1H and 13C nuclear magnetic resonance spectroscopy.The optimum process conditions of asymmetric addition reactions were determined using 2-MeTHF/toluene as solvent,at 0.45 mol/L of 4-chloro-2-(trifluoro acetyl),mole ratio of 4-chloro-2-(trifluoro acetyl)aniline(/1R,2S)-1-phenyl-2-(pyrrolidinyl)-1-propanol/Zinc chloride of 1.0∶1.2∶1.3.Under above conditions,the total yield reaches 79.8%(calculated by p-chloroaniline)and the enantiomeric excess is 98.2%.The improved process has the characteristics of lower cost,higher yield,which is suitable for industrial production.
作者 李灿 张方方 周毅博 王波 祝航 吴广文 LI Can;ZHANG Fangfang;ZHOU Yibo;WANG Bo;ZHU Hang;WU Guangwen(Hubei Key Laboratory of Novel Chemical Reactor&Green Chemical Technology(Wuhan Institute of Technology),Wuhan 430205,China)
出处 《武汉工程大学学报》 CAS 2020年第5期496-500,共5页 Journal of Wuhan Institute of Technology
基金 国家自然科学基金(51773159)。
关键词 依非韦伦 中间体 不对称合成 工艺优化 efavirenz intermediates asymmetric synthesis process optimization
  • 相关文献

参考文献6

二级参考文献51

  • 1赵海涛,张庆文.人免疫缺陷病毒感染的药物预防[J].世界临床药物,2013,34(1):55-58. 被引量:2
  • 2Richman D,Bozette S,Morton S,et al.The prevalence of antiretroviral drug resistance in the US[A].Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy[C].Chicago,December 16-19,2001.Washington,D.C.:American Society for Microbiology,2001.
  • 3Little SJ,Holte S,Routy J-P,et al.Antiretroviral-drug resistance among patients recently infected with HIV[J].N Engl J Med,2002,347:385-394.
  • 4Grant RM,Hecht FM,Warmerdam M,et al.Time trends in primary HIV-1 drug resistance among recently infected persons[J].JAMA,2002,288:181-188.
  • 5Yeni PG,Hammer SM,Carpenter CC,et al.Antiretroviral treatment for adult HIV infection in 2002:updated recommendations of the International AIDS Society-USA Panel[J].JAMA,2002,288:222-235.
  • 6Shet A,Markowitz M.Transmitted multidrug resistant HIV-1:new and investigational therapeutic approaches[J].Curr Opin Investig Drugs,2006,7(8):709-720.
  • 7Fox J,Dustan S,McClure M,et al.transmitted drug-resistant HIV-1 in primary HIV-1 infection:incidence,evolution and impact on response to antiretroviral therapy[J].HIV Med,2006;7:477-483.
  • 8Vergne L,Diagbouga S,Kouanfack C,et al.HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon[J].Antivir Ther,2006,11(5):575-579.
  • 9Ross LL,Dretler R,Gerondelis P,et al.A rare HIV reverse transcriptase mutation,K65N,confers reduced susceptibility to tenofovir,lamivudine and didanosine[J].AIDS,2006,20(5):787-789.
  • 10Gianotti N,Galli L,Boeri E,et al.The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients[J].J Acquir Immune Defic Syndr,2006,41(4):447-452.

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部